Antonino Farulla

Antonino Farulla

Auto-generated profile, based on publicly available information

Antonino Farulla

Univ Modena & reggio emilia, Unit Minimally Invas & Robot Gynecol Surg, AOU Policlin Modena, Via Pozzo 71, I-41125 Modena, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2018 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
GGGiovanni Grandi
Giovanni Grandi
AFAntonino Farulla
Antonino Farulla
FSFilomena Giulia Sileo
Filomena Giulia Sileo
FFFabio Facchinetti
Fabio Facchinetti
The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be particularly suitable in nulliparous women. While LNG-IUSs 13.5, 19.5 mg and LNG 52 mg should be used by women simply looking for an effective contraceptive method for up to 3, 4 or 5 years, LNG-IUS 52 mg has also been approved for the treatment of heavy menstrual bleeding and endometrial protection during hormone replacement therapy. LNG-IUS 52 mg is ideal for women who are experiencing a certain hyperestrogenic hormonal environment, with heavy menstrual bleeding due to hormonal imbalances, adenomyosis or fibroids, in the case of symptomatic endometriosis or for endometrial protection during hormone estrogenic replacement therapy in non-hysterectomized women.

25 September 2018 in Journal of Radiology Case Reports
Verified
Journal Article
Open access
ASAmbra Cassar Scalia
Ambra Cassar Scalia
AFAntonino Farulla
Antonino Farulla
FFFederica Fiocchi
Federica Fiocchi
CACarlo Alboni
Carlo Alboni
PTPietro Torricelli
Pietro Torricelli
Gorlin-Goltz Syndrome also known as Nevoid Basal Cell Carcinoma Syndrome is an autosomal dominant multisystem disorder. It is characterized by basal cell carcinomas, odontogenic keratocysts, skeletal abnormalities and in a minority of female patients bilateral calcified ovarian fibromas. It is challenging to radiologically assess ovarian fibromas as they have similar imaging patterns to some malignant ovarian lesions. However, it is vitally important to differentiate between benign and malignant lesions to determine patients' suitability for fertility-sparing surgery. This report describes a case of a 25 year-old patient with Gorlin-Goltz Syndrome and bilateral ovarian fibromas.

1 November 2023 in Minerva Obstetrics and Gynecology
Verified
Journal Article
Closed access
CACarlo Alboni
Carlo Alboni
SMSimona Melegari
Simona Melegari
LMLudovica Camacho Mattos
Ludovica Camacho Mattos
AFAntonino Farulla
Antonino Farulla
Article: Effects of osteopathic manipulative therapy on recurrent pelvic pain and dyspareunia in women after surgery for endometriosis: a retrospective study - Minerva Obstetrics and Gynecology 2023 Nov 23 - Minerva Medica - Journals

1 January 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
CACarlo Alboni
Carlo Alboni
AFAntonino Farulla
Antonino Farulla
FFFabio Facchinetti
Fabio Facchinetti
AEAlfredo Ercoli
Alfredo Ercoli

1 January 2025 in Minerva Obstetrics and Gynecology
Verified
Journal Article
Closed access
CACarlo Alboni
Carlo Alboni
MCMarianna Cannoletta
Marianna Cannoletta
SMSara Mosca
Sara Mosca
SPSilvia Pasini
Silvia Pasini
AFAntonino Farulla
Antonino Farulla
GCGiuseppe Chiossi
Giuseppe Chiossi
Article: Endometriosis and risk factors in pregnancy, labor and delivery: a case-control study - Minerva Obstetrics and Gynecology 2024 Nov 08 - Minerva Medica - Journals

24 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CACarlo Alboni
Carlo Alboni
SZSofia Gambigliani Zoccoli
Sofia Gambigliani Zoccoli
NVNunzia Del Villano
Nunzia Del Villano
MGMartina Di Gianvito
Martina Di Gianvito
RCRiccardo Cuoghi Costantini
Riccardo Cuoghi Costantini
AMAntonio La Marca
Antonio La Marca
PurposeTo evaluate whether the ultrasound-based #Enzian classification provides prognostic information on fertility in women with endometriosis, and whether it can be used as a tool for individualized counselling regarding the likelihood of spontaneous and ART-assisted conception.MethodsWe conducted a retrospective cohort study at a tertiary referral center (2018-2023). From 723 women with endometriosis, 78 met the inclusion criteria: ultrasound-confirmed disease, active desire for pregnancy, and no hormonal therapy or surgery at baseline. Patients were followed for a median of 48 months (range 14-60). Clinical, sonographic, reproductive, and surgical data were collected. Associations between #Enzian compartments and pregnancy outcomes were analysed using Cox regression adjusted for male factor infertility.ResultsFifty-five of 78 women (70.5%) achieved pregnancy, with a live birth (LB) rate of 44.9% and a median time to pregnancy (TTP) of 24 months, confirming subfertility in this population. Among them, 36 conceived spontaneously and 19 through ART. During follow-up, 36 women (46.2%) underwent surgery after failed spontaneous attempts and worsening symptoms; 19 conceived postoperatively, resulting in 15 LB, with a median TTP of 36 months. Adenomyosis (F.A) and right tubo-ovarian adhesions (T.right) were significantly associated with reduced pregnancy rates (HR 0.27 and 0.74, respectively) and both negatively influenced ART success (HR for F.A 0.25). Compartment A (rectovaginal space and vagina) involvement was linked to significantly longer TTP (+10.2 months, p=0.020).ConclusionWomen with endometriosis are subfertile, with prolonged TTP and reduced LB rates. The ultrasound-based #Enzian classification provides compartment-specific prognostic information, supporting its role as a non-invasive tool to refine fertility counselling and guide clinical management.